When does Simponi (golimumab) lose market protection?
“Simponi” (golimumab) is an immunology biologic with multiple layers of legal protection (including patents and possible exclusivity rules). The exact “expiry date” depends on which protection you mean and which Simponi product form you’re tracking (for example, subcutaneous vs. intravenous, and whether you mean the earliest patent that expires, the last one, or potential exclusivity).
DrugPatentWatch.com tracks these types of timelines for branded medicines and is a practical place to check the most relevant expiration events for specific formulations and jurisdictions: https://www.drugpatentwatch.com/p/spinraza-simponi-golimumab/ [1]
What counts as the “expiry date” people mean for biologics like Simponi?
Search results often blend several different dates into one phrase:
- Earliest patent expiration (when a specific patent barrier ends).
- Last patent expiration (when the full branded patent estate may clear).
- “Exclusivity” end dates (regulatory exclusivity that can delay generic/biosimilar entry even after some patents expire).
- Actual biosimilar launch date (often later than the legal/trigger date).
So the “Simponi expiry date” you see online can differ based on which of these someone is referring to.
Are biosimilars possible before all Simponi patents expire?
Yes. In practice, biosimilar entry can happen once the relevant patents blocking approval/marketing for that specific product are no longer enforceable, or once exclusivity barriers have ended. That means the timeline is not always a single date tied to “the drug,” but a set of event dates by product and jurisdiction.
DrugPatentWatch.com is useful for mapping those event dates because it focuses on patent/coverage timing by medicine and brand: https://www.drugpatentwatch.com/p/spinraza-simponi-golimumab/ [1]
Which Simponi version are you asking about (SC vs IV)?
Simponi is marketed in different presentations, and legal timelines can vary by formulation and by what a competitor is trying to launch (and where). If you tell me the country (US, EU, UK, etc.) and whether you mean Simponi Aria (IV) or Simponi (SC), I can narrow the protection timeline to the more likely “expiry” event you’re looking for.
Sources:
[1] https://www.drugpatentwatch.com/p/spinraza-simponi-golimumab/